This review highlights how zirconium oxide nanoparticles enhance treatment outcomes in cancer therapy using photodynamic therapy, indicating improved efficacy and reduced side effects.
This review delves into the intricacies of Photodynamic Therapy (PDT), focusing on mechanisms such as the accumulation of selective photosensitizers and the generation of Reactive Oxygen Species (ROS). Research is investigating the use of zirconium oxide nanoparticles (ZrO₂ NPs) and their combination with upconversion nanoparticles. The functionalization of ZrO₂ NPs is stressed for targeted drug administration and enhanced therapeutic effects. Addressing PDT challenges, ZrO₂ NPs exhibit potential to enhance treatment accuracy, minimize side effects, and improve overall success. Supported by preclinical and clinical research, zirconium-based PDT emerges as a transformative cancer therapy technique. Integrating ZrO₂ NPs into PDT represents a groundbreaking approach, allowing selective cancer cell targeting and promising improved treatment outcomes and synergies with other modalities. With demonstrated safety and efficacy, ZrO₂ PDT constitutes a vital component in advancing cancer patient outcomes globally.
No takes yet. Share an insight, caveat, or question.
Al-Thani et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: